FDA approved Veklury (remdesivir) to treat COVID-19. It is indicated for adults and pediatric patients (12 years of age and older and weighing at least 40 kg) for the treatment of coronavirus disease 2019 (COVID-19) requiring hospitalization. This drug is given intravenously to hospitalized patients. Remdesivir is a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor. Remdesivir is contraindicated in patients with hypersensitivity.

Warnings and Precautions while using Remdesivir

  • Elevated transaminase activity, requires monitoring of hepatic function prior to and during use of Veklury;
  • Risk of reduced antiviral activity when coadministered with chloroquine phosphate or hydroxychloroquine sulfate;
  • Hypersensitivity

Coronavirus Vaccines and Therapeutics